A world free from tuberculosis
Sandoz has taken up the challenge of stamping out TB and is committed to providing life-saving drugs to TB patients in the developing world. We are one of the world’s major manufacturers of anti-TB medicines, with state-of-the-art manufacturing facilities in South Africa, Bangladesh, Egypt, Pakistan and India dedicated to their production. Sandoz is contributing to the eradication of TB in a number of ways, both individually and as part of Novartis:
* The “Joint Efforts to Eradicate Tuberculosis” (JEET) project in India is a combined effort between patients, the public and Sandoz. Through various measures within JEET, Sandoz endeavors to create awareness of tuberculosis and at the same time control the spread of the disease.
* Novartis has committed to donating gold-standard anti-TB formulations to the World Health Organization for the treatment of half a million patients over a five-year period from 2004.
* Novartis (India) Limited is working with the “Global TB Alliance for TB Drug Development”. A new drug is expected to be available by 2010.
* The Novartis Institute of Tropical Diseases (NITD) in Singapore carries out research into drugs for tropical diseases such as malaria, dengue, TB, etc.
* The “Joint Efforts to Eradicate Tuberculosis” (JEET) project in India is a combined effort between patients, the public and Sandoz. Through various measures within JEET, Sandoz endeavors to create awareness of tuberculosis and at the same time control the spread of the disease.
* Novartis has committed to donating gold-standard anti-TB formulations to the World Health Organization for the treatment of half a million patients over a five-year period from 2004.
* Novartis (India) Limited is working with the “Global TB Alliance for TB Drug Development”. A new drug is expected to be available by 2010.
* The Novartis Institute of Tropical Diseases (NITD) in Singapore carries out research into drugs for tropical diseases such as malaria, dengue, TB, etc.